Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-I and insulin-like growth factor binding protein-3: A 2-year, double-blind, placebo-controlled study

Fertility and Sterility

Volumn 82, Issue 2, 2004, Pages 384-390

  Duschek, Erik J J ^a   De Valk De Roo, Gerdien W ^a   Gooren, Louis J ^a   Netelenbos, Coen ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

conjugated estrogens; IGF I; IGF I IGFBP 3 ratio; IGFBP 3; Postmenopause; raloxifene

Indexed keywords

CONJUGATED ESTROGEN; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYSTERECTOMY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYSTERECTOMY; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; TIME FACTORS;

EID: 4143062444     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.01.033     Document Type: Article

References (59)

1. LeRoith D., McGuinness M., Shemer J., et al. Insulin-like growth factors. Biol Signals. 1:(4):1992;173-181
2. Sjogren K., Liu J.L., Blad K., Skrtic S., Vidal O., Wallenius K., et al. Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA. 96:(12):1999;7088-7092
3. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996;Suppl 43:S57-S63
4. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:(1):2000;1-9
5. Khan A.S., Sane D.C., Wannenburg T., Sonntag W.E. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res. 54:(1):2002;25-35
6. Sowers J.R. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension. 29:(3):1997;691-699
7. Bayes-Genis A., Conover C.A., Schwartz R.S. The insulin-like growth factor axis a review of atherosclerosis and restenosis. Circ Res. 86:(2):2000;125-130
8. Janssen J.A., Lamberts S.W. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus is prevention possible? Eur J Endocrinol. 146:(4):2002;467-477
9. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res. 12:(8):1997;1272-1279
10. Seck T., Scheidt-Nave C., Leidig-Bruckner G., Ziegler R., Pfeilschifter J. Low serum concentrations of insulin-like growth factor-I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf). 55:(1):2001;101-106
11. Munoz-Torres M., Mezquita-Raya P., Lopez-Rodriguez F., Torres-Vela E., de Dios L.J., Escobar-Jimenez F. The contribution of IGF-I to skeletal integrity in postmenopausal women. Clin Endocrinol (Oxf). 55:(6):2001;759-766
12. Krattenmacher R., Knauthe R., Parczyk K., Walker A., Hilgenfeldt U., Fritzemeier K.H. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I direct and indirect estrogen effects. J Steroid Biochem Mol Biol. 48:(2-3):1994;207-214
13. Holmes M.D., Pollak M.N., Hankinson S.E. Lifestyle correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev. 11:(9):2002;862-867
14. Paassilta M., Karjalainen A., Kervinen K., Savolainen M.J., Heikkinen J., Blackstrom A.C., et al. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy relation to lipoprotein(a) levels. Atherosclerosis. 149:(1):2000;157-162
15. Weissberger A.J., Ho K.K., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 72:(2):1991;374-381
16. Cano A., Castelo-Branco C., Tarin J.J. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone- stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertil Steril. 71:(2):1999;261-267
17. Vongpatanasin W., Tuncel M., Wang Z., Arbique D., Mehrad B., Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol. 41:(8):2003;1358-1363
18. Goodman-Gruen D., Barrett-Connor E. Effect of replacement estrogen on insulin- like growth factor-I in postmenopausal women the Rancho Bernardo Study. J Clin Endocrinol Metab. 81:(12):1996;4268-4271
19. Johnston C.C. Jr, Bjarnason N.H., Cohen F.J., Shah A., Lindsay R., Mitlak B.H., et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women three-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med. 160:(22):2000;3444-3450
20. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 282:(7):1999;637-645
21. de Valk-de Roo G.W., Stehouwer C.D., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 19:(12):1999;2993-3000
22. Mijatovic V., van der Mooren M.J., Kenemans P., de Valk-de Roo G.W., Netelenbos C. Raloxifene lowers serum lipoprotein (A) in healthy postmenopausal women a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause. 6:(2):1999;134-137
23. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:(18):1998;1445-1451
24. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:(23):1997;1641-1647
25. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:(2):2001;125-134
26. Andersson B., Johannsson G., Holm G., Bengtsson B.A., Sashegyi A., Pavo I., et al. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus a randomized clinical trial. J Clin Endocrinol Metab. 87:(1):2002;122-128
27. Seck T., Scheppach B., Scharla S., Diel I., Blum W.F., Bismar H., et al. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab. 83:(7):1998;2331-2337
28. Cardim H.J., Lopes C.M., Giannella-Neto D., da Fonseca A.M., Pinotti J.A. The insulin-like growth factor-I system and hormone replacement therapy. Fertil Steril. 75:(2):2001;282-287
29. Kam G.Y., Leung K.C., Baxter R.C., Ho K.K. Estrogens exert route- and dose- dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid- labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 85:(5):2000;1918-1922
30. Oleksik A.M., Duong T., Pliester N., Asma G., Popp-Snijders C., Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab. 86:(6):2001;2763-2768
31. Stomati M., Hartmann B., Spinetti A., Mailand D., Rubino S., Albrecht A., et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest. 19:(8):1996;535-541
32. Posaci C., Altunyurt S., Islekel H., Onvural A. Effects of HRT on serum levels of IGF-I in postmenopausal women. Maturitas. 40:(1):2001;69-74
33. Campagnoli C., Ambroggio S., Biglia N., Sismondi P. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol. 13:(Suppl 6):1999;13-19
34. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor-I is associated with increased risk of ischemic heart disease a population-based case-control study. Circulation. 106:(8):2002;939-944
35. Angerer P., Stork S., Kothny W., Schmitt P., von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 21:(2):2001;262-268
36. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 288:(1):2002;49-57
37. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:(3):2002;321-333
38. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287:(7):2002;847-857
39. Mosca L., Barrett-Connor E., Wenger N.K., Collins P., Grady D., Kornitzer M., et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol. 88:(4):2001;392-395
40. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women a randomized, controlled trial. J Clin Endocrinol Metab. 85:(1):2000;214-218
41. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 91:(7):1999;620-625
42. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:(9113):1998;1393-1396
43. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998;(5350 VI):563-566
44. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., et al. Insulin-like growth factor-1 and prostate cancer risk a population-based, case-control study. J Natl Cancer Inst. 90:(12):1998;911-915
45. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk a case-control analysis. J Natl Cancer Inst. 91:(2):1999;151-156
46. Karey K.P., Sirbasku D.A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 48:(14):1988;4083-4092
47. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 62:(4):2002;1030-1035
48. Li B.D., Khosravi M.J., Berkel H.J., Diamandi A., Dayton M.A., Smith M., et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer. 91:(5):2001;736-739
49. Byrne C., Colditz G.A., Willett W.C., Speizer F.E., Pollak M., Hankinson S.E. Plasma insulin-like growth factor (IGF)-I, IGF-binding protein 3, and mammographic density. Cancer Res. 60:(14):2000;3744-3748
50. Campbell M.J., Woodside J.V., Secker-Walker J., Titcomb A., Leathem A.J. IGF status is altered by tamoxifen in patients with breast cancer. Mol Pathol. 54:(5):2001;307-310
51. Pollak M., Costantino J., Polychronakos C., Blauer S.A., Guyda H., Redmond C., et al. Effect of tamoxifen on serum insulin-like growth factor-I levels in stage I breast cancer patients. J Natl Cancer Inst. 82:(21):1990;1693-1697
52. Helle S.I., Holly J.M., Tally M., Hall K., Vander S.J., Lonning P.E. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer. 69:(4):1996;335-339
53. Torrisi R., Baglietto L., Johansson H., Veronesi G., Bonnani B., Guerriera-Gonzaga A., et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer. 85:(12):2001;1838-1841
54. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 281:(23):1999;2189-2197
55. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:(4):2000;485-491
56. Gamero P., Sornay-Rendu E., Delmas P.D. Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women. Lancet. 355:(9207):2000;898-899
57. Langlois J.A., Rosen C.J., Visser M., Hannan M.T., Harris T., Wilson P.W., et al. Association between insulin-like growth factor-I and bone mineral density in older women and men the Framingham Heart Study. J Clin Endocrinol Metab. 83:(12):1998;4257-4262
58. Nasu M., Sugimoto T., Chihara M., Hiraumi M., Kurimoto F., Chihara K. Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol. 136:(6):1997;608-616
59. Rosen C.J. IGF-I and osteoporosis. Clin Lab Med. 20:(3):2000;591-602